Onchilles Pharma is pioneering a new class of cancer drugs that exploit the ELANE pathway, a vulnerability tied to elevated histone H1 levels in many tumors. Its lead asset, N17350 (NEU-001), is a tumor-directed biologic shown in preclinical studies to induce rapid, selective tumor cell death and CD8+ T-cell activation across 30 cancer cell lines and 15 in-vivo models, including chemotherapy-resistant and immunologically “cold” tumors. The company has completed GMP manufacturing of more than 5,000 doses and plans to start first-in-human studies in Australia in early 2025, with U.S. enrollment expected mid-2026, aiming for clinical proof-of-concept in the second half of 2026. A second program, NEU-002, a systemic version of the therapy, is on track for development-candidate nomination in early 2026. The firm positions its ELANE-based drugs as next-generation cytotoxics that combine potent tumor killing with immune preservation and activation, potentially addressing a broad range of solid tumors. To date, Onchilles has raised $40 million in Series A financing, including the latest $25 million Series A1 tranche to fund clinical development of N17350.

Total raised

$32M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2025